Fair Pricing of Innovative Medicines: An EHA Position Paper
Hemasphere
.
2020 Sep 30;4(5):e488.
doi: 10.1097/HS9.0000000000000488.
eCollection 2020 Oct.
Authors
Anton Hagenbeek
1
,
John Gribben
2
,
Ulrich Jäger
3
,
Peter Kapitein
4
,
Giampaolo Merlini
5
,
Maria Piggin
6
,
Carin A Uyl-de Groot
7
8
,
Robin Doeswijk
9
Affiliations
1
Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
2
Barts Cancer Institute, Queen Mary University of London, London, UK.
3
Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Vienna, Austria.
4
Inspire2Live, Amsterdam, The Netherlands.
5
Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy.
6
PNH Support, a Charitable Incorporated Organization registered with the Charities Commission of England and Wales (no. 1161518), London, UK.
7
Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.
8
Institute for Medical Technology Assessment, Rotterdam, The Netherlands.
9
European Hematology Association, The Hague, The Netherlands.
PMID:
33134863
PMCID:
PMC7544294
DOI:
10.1097/HS9.0000000000000488
No abstract available
Publication types
Editorial